Zyprexa US prosecutor: "Expect more off-label cases"
This article was originally published in Scrip
Executive Summary
The Acting US Attorney for Eastern District of Pennsylvania, Laurie Magid, who was very much involved in reaching the $1.4 billion settlement with Lilly regarding alleged off-label promotion of Zyprexa (olanzapine), has indicated that more of these kinds of cases should be expected. The Lilly financial settlement, announced in late January, was the largest against a single company in the history of the Department of Justice.